Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Binimetinib + Nivolumab +/- Ipilimumab in MSS RAS-mutant mCRC
NCT03271047Phase 2Completed
- Sponsor
- Pfizer
- Start
- Oct 2017
- Primary completion
- Oct 2020
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, randomised, open-label trial of binimetinib in colorectal cancer (CRC) (4 arms), sponsored by Pfizer. Primary endpoints: Dose-Limiting Toxicities and Objective Response Rate up to 26 months. Started Oct 2017; status: completed.
02
Drugs
binimetinib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT03271047.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03271047.